A Phase I, Open-label, Dose-escalation Study of the Safety and Pharmacokinetics of IMP4297 in Patients With Advanced Solid Tumors
Latest Information Update: 21 Jan 2025
Price :
$35 *
At a glance
- Drugs Senaparib (Primary)
- Indications Advanced breast cancer; Carcinoma; Fallopian tube cancer; Male breast cancer; Ovarian cancer; Peritoneal cancer; Prostate cancer; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors IMPACT Therapeutics
- 27 Mar 2021 Status changed from active, no longer recruiting to completed.
- 02 Feb 2021 Planned End Date changed from 31 Dec 2020 to 30 Jun 2021.
- 22 Nov 2020 Planned End Date changed from 31 Oct 2021 to 31 Dec 2020.